Eloralintide is the first pure amylin receptor agonist for weight loss, a completely new mechanism separate from all GLP-1 drugs. Phase 2 showed up to 20.1% weight loss. The Phase 3 ENLIGHTEN trial began enrolling in December 2025.
The first pure amylin agonist with a completely new mechanism separate from all GLP-1 drugs. Phase 2 showed up to 20.1% weight loss. The Phase 3 ENLIGHTEN trial is now enrolling.
A weekly injection using a completely new pathway, amylin, separate from all existing GLP-1 drugs. Every approved GLP-1 drug works through the same basic family of receptors. Eloralintide doesn't. It opens an entirely new door.
Every weight loss injection you've heard of, Wegovy, Zepbound, Ozempic, works on GLP-1 receptors (and sometimes GIP). They suppress hunger by targeting a specific set of pathways. Eloralintide does something completely different: it targets amylin receptors.
Amylin is a hormone your body naturally releases alongside insulin after meals. It signals satiety through a distinct gut-brain pathway that GLP-1 drugs don't touch. Eloralintide amplifies this signal, independently. That's why it could work even in people who didn't fully respond to GLP-1 drugs, and why combining it with a GLP-1 drug could produce additive effects.
CagriSema (already filed for FDA approval) already showed this combined approach works: it pairs semaglutide (a GLP-1) with cagrilintide (an amylin analog) and produced 22.7% weight loss in Phase 3. Eloralintide is the first pure amylin agonist, no GLP-1 component, which makes it unique.
Amylin and GLP-1 are completely separate hormones with separate receptors. Eloralintide activates one GLP-1 drugs don't touch. Amylin and GLP-1 signal fullness through different brain and gut receptors. This is what makes eloralintide both novel and potentially combinable with existing drugs.
Once-weekly subcutaneous injection into the abdomen, thigh, or arm. Dose is escalated gradually over the first weeks to minimize GI side effects.
Eloralintide binds selectively to amylin receptors throughout your digestive tract and in specific brain regions, a pathway entirely distinct from GLP-1.
Satiety signals are amplified through this independent gut-brain circuit. You feel full sooner and stay full longer, through a mechanism no approved drug uses.
48-week results published in The Lancet and presented at ObesityWeek 2025. All doses beat placebo. The Phase 2 data was published in The Lancet and presented at ObesityWeek 2025. The trial ran 48 weeks across multiple dose cohorts. Every active dose outperformed placebo, with a clear dose-response relationship.
GLP-1 drugs work well for most people, but not everyone. Some patients plateau, others don't respond as strongly. Because eloralintide works through a completely different receptor, it could help people who haven't gotten results from GLP-1 drugs. More importantly, it could eventually be combined with GLP-1 drugs for greater weight loss, similar to how CagriSema combines semaglutide with an amylin analog.
Phase 3 ENLIGHTEN trial enrolling. FDA decision expected 2028-2029. Phase 2 data published in late 2025. Phase 3 ENLIGHTEN trials are now actively recruiting. FDA decision not expected until 2028 at the earliest.
Phase 3 ENLIGHTEN trials are actively enrolling. You'd get the drug at no cost with close medical supervision.
Search Open Trials →"Most people in this space talk about GLP-1 and stop there. Amylin is a real part of how the body signals fullness and it's been mostly ignored in the drug development conversation. Eloralintide is one of the few taking it seriously."
Endocrine Surgeon · GLP-1 Specialist
Not available yet. But here's who benefits most, especially people who didn't get results from GLP-1 drugs. Eloralintide isn't approved yet. But its novel mechanism makes it particularly interesting for specific patient profiles.
⚕️ Always consult your doctor before starting or changing any weight loss treatment.
Eloralintide vs other pipeline drugs and what's currently approved. The most honest comparison is mechanism, eloralintide operates in a different lane from GLP-1 drugs entirely.
| Drug | Weight Loss | Mechanism | Form | Status |
|---|---|---|---|---|
| 💉Eloralintide You're here | 20% (Ph2) | Pure Amylin Agonist | Weekly injection | Phase 3 |
| 💉Retatrutide | 24% (Ph2) | Triple Agonist (GLP-1/GIP/Glucagon) | Weekly injection | Phase 3 |
| 💉CagriSema | 22.7% (Ph3) | GLP-1 + Amylin | Weekly injection | NDA Filed |
| 💉Zepbound | 21% | Dual Agonist (GLP-1, GIP) | Weekly injection | ✓ Approved |
| 💉Wegovy | 15% | GLP-1 Agonist | Weekly injection | ✓ Approved |
Phase 2 numbers are from clinical trials, not direct drug-to-drug comparisons. Interpret any cross-trial numbers carefully.